SPN-817

DRUG3 trials

Sponsors

Supernus Pharmaceuticals, Inc.

Conditions

EpilepsyFocal Onset SeizuresSeizures, Epileptic

Phase 2

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

RecruitingNCT05518578

Supernus Pharmaceuticals, Inc.Epilepsy, Seizures, Epileptic

Start: 2023-02-07End: 2027-12-31Target: 60Updated: 2026-04-21

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

RecruitingNCT06798896

Supernus Pharmaceuticals, Inc.Focal Onset Seizures

Start: 2024-12-30End: 2027-08-01Target: 216Updated: 2026-06-01

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

RecruitingNCT07141329

Supernus Pharmaceuticals, Inc.Focal Onset Seizures

Start: 2025-07-30End: 2027-12-31Target: 100Updated: 2025-10-10